文献速递药疹与重症皮肤不良反应皮肤肿瘤

维莫非尼诱导的RAS病样粉刺样或囊性皮损:一种与二噁英诱导的MADISH相似但不相同的皮肤病变模型

RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-01-01

本病例系列研究探索了10例维莫非尼治疗的恶性黑色素瘤患者的皮肤病变组织学,并与二噁英诱导的MADISH进行比较。所有患者皮损被诊断为非炎症性痤疮样皮疹,组织学显示粉刺样病变和真皮囊肿,但CYP1A1表达缺失,维莫非尼及酪氨酸激酶抑制剂未诱导CYP1A1活性。作者认为这些病变不同于真正的MADISH,并非由AhR信号通路介导,而可能与维莫非尼治疗导致PI3K-Akt通路过度激活有关。

要点

  • 维莫非尼治疗患者可出现面部为主、耳后明显的非炎症性痤疮样皮疹。
  • 组织学显示粉刺样病变和含上皮壁的真皮囊肿,但CYP1A1表达阴性。
  • 维莫非尼及厄洛替尼、吉非替尼未诱导CYP1A1活性,病变不同于MADISH。

核心结论

  • 维莫非尼诱导的皮肤病变形态学上与MADISH相似,但CYP1A1表达缺失且维莫非尼不激活CYP1A1,故认为这些病变不同于真正的MADISH,并非由AhR信号通路交互作用介导,而可能与维莫非尼治疗导致PI3K-Akt通路过度激活有关。
  • 诊断MADISH需真皮囊肿上皮壁强表达CYP1A1,并与病变形态学并行,这是暴露于二噁英样/致氯痤疮化合物的标志。

研究设计与样本

  • 病例系列研究,探索了10例因恶性黑色素瘤接受维莫非尼治疗患者的皮肤病变组织学。
  • 分析了维莫非尼和酪氨酸激酶抑制剂诱导二噁英-AhR通路的能力。

主要发现

  • 所有患者的皮肤病变被皮肤科医生诊断为「非炎症性痤疮样皮疹」,主要位于面部,耳后受累明显,经二噁英专家评估临床符合氯痤疮/MADISH。
  • 组织学分析显示主要为粉刺样病变和真皮囊肿,囊肿含上皮壁,伴基底或侧向上皮突起、层状角化和残留皮脂腺改变。
  • CYP1A1(二噁英暴露后高度诱导的基因)在这些病变中未观察到表达。
  • 维莫非尼和酪氨酸激酶抑制剂厄洛替尼、吉非替尼未诱导CYP1A1活性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients treated with vemurafenib for metastatic melanoma often develop skin lesions similar to those observed after exposure to dioxin-like compounds. We previously called these lesions MADISH (metabolizing acquired dioxin-induced skin hamartoma) when analysing a case of acute dioxin poisoning. OBJECTIVE: We performed a clinical trial aimed at comparing the skin lesions observed under vemurafenib treatment with MADISH in order to bring to light a possible crosstalk between vemurafenib and dioxin pathways. METHODS: In this case series study, we explored the histological aspect of skin lesions in 10 cases treated with vemurafenib for malignant melanoma. We also analysed the ability of vemurafenib and tyrosine kinase inhibitors to induce dioxin-AhR pathway. RESULTS: All patients had skin lesions diagnosed as 'non-inflammatory acneiform eruption' by dermatologists. These were predominantly facial with notable retroauricular involvement and clinically compatible with chloracne/MADISH when assessed by dioxin expert. Histological analysis showed mostly comedone-like lesions and dermal cysts containing epithelial wall with basal or lateral epithelial projections and lamellar keratinization and alterations of remaining sebaceous glands. The expression of CYP1A1, a gene highly induced following dioxin exposure, was not observed in these lesions. Vemurafenib and the tyrosine kinase inhibitors erlotinib and gefitinib did not induce CYP1A1 activity. DISCUSSION: Although the skin lesions under vemurafenib treatment were morphologically similar to MADISH, the absence of CYP1A1 expression in dermal cysts of patients and the absence of CYP1A1 activation by vemurafenib led us consider that these skin lesions were different from true MADISH and not mediated by a crosstalk of AhR signalling, but rather to a hyperactivation of PI3K-Akt pathway as a consequence of vemurafenib treatment. A strong expression of CYP1A1 in the epithelial wall of dermal cysts must be required, parallel to the morphology of the lesions, to make the diagnosis of MADISH, the hallmark of an exposure to dioxin-like/chloracnegen compounds.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Kaya G, Saxer-Sekulic N, Kaya A, et al. RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH. J Eur Acad Dermatol Venereol. 2018. PMID: 29575357. doi:10.1111/jdv.14945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。